On September 17, Vivus announced that its obesity medication Qsymia (formerly Qnexa) is now available on the US market – this happened at least several weeks earlier...
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
96 readers recommended
Why did Qnexa become Qsymia? diaTribe investigates the thinking behind drug names… and why they’re vital to patient safety.
37 readers recommended
In March 2013, Novo Nordisk launched Tresiba (insulin degludec) , its new once-daily basal insulin for type 1 and type 2 diabetes, in the UK and Denmark. Tresiba will be...
31 readers recommended
Kelly reflects on some changes here at diaTribe and in the world of diabetes and obesity.
65 readers recommended
On August 17, the FDA approved Mylan’s new generic versions of Actos (pioglitazone), a once-daily oral tablet for the treatment of type 2 diabetes originally sold by...
36 readers recommended
Kelly on a heated day at the FDA and why a new drug class could bring diabetes patients, doctors, and educators closer to personalized therapy.
37 readers recommended
On March 1, Vivus started its Save Now! program, which sets a discounted price of $75 for one 30-day supply of the company’s weight management medication Qsymia (7.5 mg...
40 readers recommended
On June 27, the FDA approved Arena Pharmaceutical’s weight-loss drug Belviq (lorcaserin), the first weight-loss drug to be approved in the US in 13 years. Belviq is...
50 readers recommended
On August 29, J&J’s chronic pain drug Nucynta ER (tapentadol) was granted FDA approval for the management of the pain associated with diabetic peripheral neuropathy...
48 readers recommended
On January 11, an advisory panel recommended that the FDA approve Johnson & Johnson’s SGLT-2 inhibitor, Invokana (canagliflozin). The panel voted 10-5 in favor of...
22 readers recommended
Kelly reflects on a major advance in obesity treatment and highlights a memorable day for diabetes at the Major League Baseball Hall of Fame.
47 readers recommended
The 30th Annual Obesity Society Meeting brings exciting insights on drugs and mobile health.
34 readers recommended
Dr. Sanjay Kaul speaks to diaTribe about the new SGLT-2 drug class.
42 readers recommended
On July 17, the FDA approved Vivus’ weight-loss medication Qsymia (formerly called Qnexa), just several weeks after the approval of Arena’s Belviq (see new now next in...
33 readers recommended
Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) released its safety review of incretin-based therapies for diabetes. It...
44 readers recommended
On January 8, the FDA approved Farxiga (dapaglifozin) for the treatment of type 2 diabetes. The drug is called Forxiga in Europe, where it has been approved since...
30 readers recommended
On April 16, Vivus announced that the FDA approved a change to the distribution of Qsymia . Qsymia is a weight loss and weight management drug that is designed to be...
47 readers recommended
Do you ever wonder why there aren’t cheaper “generic” insulin products available? This may soon change as the patents for branded insulin begin to expire. In fact, the...
48 readers recommended
Last month, in early September, results from the DPP-4 inhibitor cardiovascular outcomes trials SAVOR-TIMI 53 (for Bristol Myers Squibb and AstraZeneca’s Onglyza) and...
48 readers recommended
On November 22, J&J/Janssen Cilags’ SGLT-2 inhibitor Invokana (canagliflozin) was approved in Europe. This makes Invokana the second SGLT-2 inhibitor approved in...